H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021)

Article  PubMed  Google Scholar 

R.S. Herbst, D. Morgensztern, C. Boshoff, The biology and management of non-small cell lung cancer. Nature 553, 446–454 (2018)

Article  CAS  PubMed  Google Scholar 

D.S. Ettinger, D.E. Wood, D.L. Aisner, W. Akerley, J.R. Bauman, A. Bharat, D.S. Bruno, J.Y. Chang, L.R. Chirieac, T.A. D’Amico, T.J. Dilling, J. Dowell, S. Gettinger, M.A. Gubens, A. Hegde, M. Hennon, R.P. Lackner, M. Lanuti, T.A. Leal, J. Lin, B.W. Loo Jr., C.M. Lovly, R.G. Martins, E. Massarelli, D. Morgensztern, T. Ng, G.A. Otterson, S.P. Patel, G.J. Riely, S.E. Schild, T.A. Shapiro, A.P. Singh, J. Stevenson, A. Tam, J. Yanagawa, S.C. Yang, K.M. Gregory, M. Hughes, NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J. Natl. Compr. Canc Netw. 19, 254–266 (2021)

Article  CAS  PubMed  Google Scholar 

J. Salami, C.M. Crews, Waste disposal-An attractive strategy for cancer therapy. Science 355, 1163–1167 (2017)

Article  CAS  PubMed  Google Scholar 

S. Narayanan, C.Y. Cai, Y.G. Assaraf, H.Q. Guo, Q. Cui, L. Wei, J.J. Huang, C.R. Ashby Jr., Z.S. Chen, Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist. Updat. 48, 100663 (2020)

Article  PubMed  Google Scholar 

G.A. Collins, A.L. Goldberg, The logic of the 26S proteasome. Cell 169, 792–806 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Schapira, M.F. Calabrese, A.N. Bullock, C.M. Crews, Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019)

Article  CAS  PubMed  Google Scholar 

T.A. Thibaudeau, D.M. Smith, A practical review of proteasome pharmacology. Pharmacol. Rev. 71, 170–197 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.J. Clague, S. Urbe, D. Komander, Breaking the chains: deubiquitylating enzyme specificity begets function. Nat. Rev. Mol. Cell. Biol. 20, 338–352 (2019)

Article  CAS  PubMed  Google Scholar 

N. Weinelt, S.J.L. van Wijk, Ubiquitin-dependent and -independent functions of OTULIN in cell fate control and beyond. Cell. Death Differ. 28, 493–504 (2021)

Article  CAS  PubMed  Google Scholar 

A. Mofers, P. Pellegrini, S. Linder, P. D’Arcy, Proteasome-associated deubiquitinases and cancer. Cancer Metastasis Rev. 36, 635–653 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

H. Yang, X. Chen, K. Li, H. Cheaito, Q. Yang, G. Wu, J. Liu, Q.P. Dou, Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Semin. Cancer Biol. 68, 105–122 (2021)

Article  CAS  PubMed  Google Scholar 

J.A. Harrigan, X. Jacq, N.M. Martin, S.P. Jackson, Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat. Rev. Drug Discov. 17, 57–78 (2018)

Article  CAS  PubMed  Google Scholar 

D. Senft, J. Qi, Z.A. Ronai, Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat. Rev. Cancer 18, 69–88 (2018)

Article  CAS  PubMed  Google Scholar 

B. Wu, L. Qiang, Y. Zhang, Y. Fu, M. Zhao, Z. Lei, Z. Lu, Y.G. Wei, H. Dai, Y. Ge, M. Liu, X. Zhou, Z. Peng, H. Li, C.P. Cui, J. Wang, H. Zheng, C.H. Liu, L. Zhang, The deubiquitinase OTUD1 inhibits colonic inflammation by suppressing RIPK1-mediated NF-kappaB signaling. Cell. Mol. Immunol. 19, 276–289 (2022)

Article  CAS  PubMed  Google Scholar 

S.M. Woo, S.U. Seo, K.J. Min, T.K. Kwon, Melatonin induces apoptotic cell death through Bim stabilization by Sp1-mediated OTUD1 upregulation. J. Pineal Res. 72, e12781 (2022)

F. Yao, Z. Zhou, J. Kim, Q. Hang, Z. Xiao, B.N. Ton, L. Chang, N. Liu, L. Zeng, W. Wang, Y. Wang, P. Zhang, X. Hu, X. Su, H. Liang, Y. Sun, L. Ma, SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity. Nat. Commun. 9, 2269 (2018)

Article  PubMed  PubMed Central  Google Scholar 

Z. Zhang, Y. Fan, F. Xie, H. Zhou, K. Jin, L. Shao, W. Shi, P. Fang, B. Yang, H. van Dam, P. Ten Dijke, X. Zheng, X. Yan, J. Jia, M. Zheng, J. Jin, C. Ding, S. Ye, F. Zhou, L. Zhang, Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nat. Commun. 8, 2116 (2017)

Article  PubMed  PubMed Central  Google Scholar 

M. Grattarola, M.A. Cucci, A. Roetto, C. Dianzani, G. Barrera, S. Pizzimenti, Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells. Free Radic. Biol. Med. 174, 202–210 (2021)

Article  CAS  PubMed  Google Scholar 

Q. Luo, X. Wu, P. Zhao, Y. Nan, W. Chang, X. Zhu, D. Su, Z. Liu, OTUD1 activates caspase-independent and caspase-dependent apoptosis by promoting AIF Nuclear translocation and MCL1 degradation. Adv. Sci. (Weinh) 8, 2002874 (2021)

Article  CAS  PubMed  Google Scholar 

H. Liu, L. Zhong, Y. Lu, X. Liu, J. Wei, Y. Ding, H. Huang, Q. Nie, X. Liao, Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1. Cell. Death Discov. 8, 403 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Deng, G. Hou, Z. Fang, J. Liu, X.D. Lv, Distinct expression and prognostic value of OTU domain-containing proteins in non-small-cell lung cancer. Oncol. Lett. 18, 5417–5427 (2019)

CAS  PubMed  PubMed Central  Google Scholar 

I.A. Mota, C.D.C. Correia, P.N. Fontana, A.A.S. Carvalho, Reducing body myopathy - a new pathogenic FHL1 variant and literature review. Neuromuscul. Disord. 31, 847–853 (2021)

Article  PubMed  Google Scholar 

X. Wei, H. Zhang, Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression. Cancer Biol. Med. 17, 270–281 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Li, Q. Zeng, J. Qiu, T. Pang, F. Ye, L. Huang, X. Zhang, Corrigendum: MiR-183-5p Promotes Proliferation, Metastasis and Angiogenesis in Breast Cancer Cells through Negatively Regulating Four and a Half LIM Protein 1. J Breast Cancer 23, 576 (2020)

Y. Liu, C. Wang, P. Cheng, S. Zhang, W. Zhou, Y. Xu, H. Xu, G. Ji, FHL1 inhibits the progression of Colorectal Cancer by regulating the Wnt/beta-Catenin signaling pathway. J. Cancer 12, 5345–5354 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Zhang, H. Li, M. Guo, J. Zhang, G. Zhang, N. Sun, Y. Feng, W. Cui, F. Xu, FHL1 as a novel prognostic biomarker and correlation with immune infiltration levels in lung adenocarcinoma. Immunotherapy (2023)

X. Wang, X. Wei, Y. Yuan, Q. Sun, J. Zhan, J. Zhang, Y. Tang, F. Li, L. Ding, Q. Ye, H. Zhang, Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter. J. Cell. Biol. 217, 1335–1351 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Thomas, C.E. Redon, L. Sciuto, E. Padiernos, J. Ji, M.J. Lee, A. Yuno, S. Lee, Y. Zhang, L. Tran, W. Yutzy, A. Rajan, U. Guha, H. Chen, R. Hassan, C.C. Alewine, E. Szabo, S.E. Bates, R.J. Kinders, S.M. Steinberg, J.H. Doroshow, M.I. Aladjem, J.B. Trepel, Y. Pommier, Phase I study of ATR inhibitor M6620 in Combination with Topotecan in patients with Advanced Solid Tumors. J. Clin. Oncol. 36, 1594–1602 (2018)

Article  CAS  PubMed  Google Scholar 

S.K. Pal, P.H. Frankel, A. Mortazavi, M. Milowsky, U. Vaishampayan, M. Parikh, Y. Lyou, P. Weng, R. Parikh, B. Teply, R. Dreicer, H. Emamekhoo, D. Michaelson, C. Hoimes, T. Zhang, S. Srinivas, W.Y. Kim, Y. Cui, E. Newman, P.N. Lara Jr., Effect of cisplatin and Gemcitabine with or without Berzosertib in patients with Advanced Urothelial Carcinoma: a phase 2 Randomized Clinical Trial. JAMA Oncol. 7, 1536–1543 (2021)

Article  PubMed  Google Scholar 

E. Lecona, O. Fernandez-Capetillo, Targeting ATR in cancer. Nat. Rev. Cancer 18, 586–595 (2018)

Article  CAS  PubMed  Google Scholar 

Q. Yin, X. Liu, L. Hu, Q. Song, S. Liu, Q. Huang, Z. Geng, Y. Zhu, X. Li, F. Fu, H. Wang, VE-822, a novel DNA holliday junction stabilizer, inhibits homologous recombination repair and triggers DNA damage response in osteogenic sarcomas. Biochem. Pharmacol. 193, 114767 (2021)

Article  CAS  PubMed  Google Scholar 

M. Wu, B. Chen, X. Pan, J. Su, Prognostic Value of Autophagy-related proteins in human gastric Cancer. Cancer Manag Res 12, 13527–13540 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

F. Ni, H. Tang, C. Wang, Z. Wang, F. Yu, B. Chen, L. Sun, Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system. Cancer Manag Res 11, 8391–8405 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

W.M. Pan, H. Wang, X.F. Zhang, P. Xu, G.L. Wang, Y.J. Li, K.P. Huang, Y.W. Zhang, H. Zhao, R.L. Du, H. Huang, X.D. Zhang, J.X. Zhang, miR-210 participates in hepatic ischemia Reperfusion Injury by forming a negative feedback Loop with SMAD4. Hepatology 72, 2134–2148 (2020)

Article  CAS  PubMed  Google Scholar 

Q. Zhang, Z.Y. Zhang, H. Du, S.Z. Li, R. Tu, Y.F. Jia, Z. Zheng, X.M. Song, R.L. Du, X.D. Zhang, DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. Cell. Death Differ. 26, 2300–2313 (2019)

Article  CAS  PubMed